Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

This week, a new paper described how researchers pieced together the entire molecular structure of the protein shell of the HIV virus using GPU-based simulations. This remarkable achievement not only ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

As the HIV virus glides up outside a human cell to dock and possibly inject its deadly cargo of genetic code, there's a spectacularly brief moment in which a tiny piece of its surface snaps open to ...

Seeing a glycoprotein on the envelope of the HIV virus snap open and shut in mere millionths of a second is giving investigators a new handle on the surface of the virus that could lead to broadly ...

Duke Human Vaccine Institute (DHVI) investigators used a technique called time-resolved, temperature-jump (TR, T-Jump) small-angle x-ray scattering (SAXS) to capture the spectacularly brief moment ...

There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...

Human Immunodeficiency Virus (HIV). The outer shell, called the capsid (yellow and purple) envelopes the viral RNA genome (blue). Illustration credit: Janet Iwasa Accomplishing a feat that had been a ...